vetmedin®

IMPROVING OUTCOMES FOR DOGS WITH HEART DISEASE

Evaluation of treatment options for preclinical heart disease

- The detection of a murmur along with cardiac enlargement during the preclinical phase used to mean watching and waiting.
- Recent studies have analysed if treatment in the preclinical stage can delay the onset of clinical symptoms of congestive heart failure (CHF).

STUDY	OBJECTIVE	STUDY DESIGN	INTERIM ANALYSIS	RESULTS SUMMARY
EPIC STUDY[1]	The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study evaluated if long-term administration of VETMEDIN® to dogs with Stage B2 myxomatous mitral valve disease (MMVD) would delay onset of clinical signs of CHF, cardiac-related death, or euthanasia.	34 INDEPENDENT CARDIOLOGISTS 11 COUNTRIES 360 DOGS OVER 4-YEAR PERIOD DOUBLE-BLINDED PLACEBO-CONTROLLED 36 CENTRES	Evidence to stop study early YES	15-MONTH DELAY to the onset of heart failure 60% MORE TIME in asymptomatic Stage B2 of heart disease† 10% MORE LIFE without CHF signs that impact quality of life or cardiac-related death‡
DELAY STUDY*	The DELAY Study evaluated the efficacy of spironolactone and benazepril in delaying onset of clinical signs in dogs with symptomatic mitral valve disease and cardiac enlargement (Stage B2).	FEWER CARDIOLOGISTS 184 DOGS OVER 8-YEAR PERIOD SINGLE-BLINDED PLACEBO-CONTROLLED 3 COUNTRIES 21 CENTRES	Evidence to stop study early NO	0-MONTH DELAY to the onset of heart failure 0% DELAY to the onset of clinical signs 0% BENEFIT in a patient's life with preclinical disease

For dogs with preclinical (Stage B2) MMVD, **VETMEDIN®** is the:

- **FIRST** approved treatment
- **ONLY** strongly recommended treatment in the **ACVIM consensus guidelines**[2]

Boehringer Ingelheim

EPIC CHANGES EVERYTHING

LEADING THE WAY IN CANINE CARDIOLOGY

For 20 years, VETMEDIN® has been revolutionising the field of canine cardiology, giving dogs with heart disease more time—more time to play, to spend with their families, to live.

1999

vetmedin®

Launch of VETMEDIN® for the treatment of dogs with congestive heart failure (CHF).

2006

VETSCOPE STUDY

Dogs with CHF due to valvular disease that were treated with VETMEDIN® showed[3]:

SIGNIFICANTLY FASTER & GREATER IMPROVEMENT in clinical signs than those on benazepril.

2008

QUEST STUDY

Dogs with CHF due to valvular disease that were **treated with VETMEDIN® and diuretic lived almost twice as long** compared with those on benazepril and diuretic.[4]

267 DAYS FOR VETMEDIN®

VS.

140 DAYS FOR BENAZEPRIL

2012

2PROTECT STUDY

For the first time ever, **VETMEDIN® delays the onset of CHF in Doberman pinschers** with preclinical dilated cardiomyopathy (DCM).[5]

PRECLINICAL DCM

2016 and 2018

THE EPIC STUDY

The EPIC Study showed that dogs in Stage B2 of preclinical heart disease treated with VETMEDIN® demonstrated[1]:

15-MONTH DELAY in time to onset of CHF or cardiac-related death†

* DELay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril.

† The composite primary endpoint was defined as the onset of left-sided CHF, cardiac-related death, or euthanasia; dogs in the VETMEDIN® group were significantly less likely to reach this endpoint. Median time to composite primary endpoint was 1228 days in the VETMEDIN® group and 766 days in the placebo group (P=0.0038).

‡ Ten percent more life without CHF was calculated based on an estimated lifespan for all small- to medium-sized dogs being 12.5 years. Fifteen months is equal to 1.25 years, which is 10% of 12.5 years.

References: 1. Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study—a randomized clinical trial. *J Vet Intern Med.* 2016;30(6):1765–1779. **2.** Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. *J Vet Intern Med.* 2019;33(3):1127–1140. **3.** Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. *J Am Anim Hosp Assoc.* 2006;42(4):249–261. **4.** Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. *J Vet Intern Med.* 2008;22(5):1124–1135. **5.** Summerfield NJ, Boswood A, O'Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT study). *J Vet Intern Med.* 2012;26(1):1337–1349.

vetmedin®

TODAY. NOT ONE DAY.



Boehringer Ingelheim

EPIC CHANGES EVERYTHING